Sign In
14 Jul 2010 07:00
ο»Ώ
Wednesday 14 July 2010
Β
Β
Cyprotex PLC
("Cyprotex" or the "Company")
Β
AGM Statement
Β
Β
Cyprotex (AIM:CRX), the drug discovery technology and information company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:
Β
"In 2009 we delivered a resilient performance in a difficult market. Revenues hit Β£5m for the second successive year and we also delivered our second year of profitability. We doubled the number of strategic customers and added 20 new customers in total.
Β
"In the current year, Cyprotex has experienced a strong second quarter and this momentum has continued into July. The Company's revenue and EBITDA performance is in line with market expectations. Furthermore, the Company will open a new laboratory in the coming weeks which will double capacity and allow the launch of our new toxicology offerings."
Β
Cyprotex expects to announce its interim results for the six months to 30 June 2010 on Thursday 12 August 2010.
Β
Β
Β
For further information:
Β
|
Cyprotex PLC |
Tel: +44 (0) 1625 505 100 |
|
|
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer |
|
|
|
ir@cyprotex.com |
www.cyprotex.com |
|
|
|
|
|
|
Singer Capital Markets Ltd |
Tel: +44 203 205 7500Β |
|
|
Shaun Dobson |
|
|
|
Claes SpΓ₯ng |
www.singercm.com |
|
|
|
|
|
|
Financial Dynamics |
Tel: +44 (0) 20 7831 3113 |
|
|
Ben Brewerton / Ben Atwell / Mo Noonan |
|
|
|
cyprotex@fd.com |
www.fd.com |
|
Β
Β
Follow the stocks
